Monthly Archives: June 2018

Effective June 25, there will be a separation of the VU and VUMC point-of-sale and debit systems. For VUMC employees, Commodore Cash will become Badge Bucks. Continue reading →

After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeede… Continue reading →

The deadline to submit your annual self-evaluation is June 22. All VUMC staff will need to complete a self-evaluation in Performance Central on the HR Website. Continue reading →

The Joint Commission will conduct a follow-up visit to review a few opportunities for improvement around suicidal ideation assessments for incoming patients, physical space modifications for patients across VUMC with behavioral health diagnoses and rep… Continue reading →

We would like to thank Baihui Liu, Kuiran Dong, and Rui Dong as well as Ana Savić Mlakar, Iva Hojsak, and Krešo Bendelja for their interest in our article.1 We read their letters with great interest and provide our response herein. Continue reading →

In some patients with extreme phenotypes of inflammatory bowel disease (IBD; in particular in those with infantile or very early onset IBD with <6 years of onset, nonresponsiveness to therapy, or extraintestinal manifestations), Mendelian forms of IBD have been described.1 To identify patients with Mendelian disease-associated IBD in a cohort with age at diagnosis between 7 and 40 years of age, we screened for 59 Mendelian forms of IBD by exome sequencing across 503 patients with IBD with severe disease, as indicated by need for intestinal surgery and/or therapy progression to biologics (Supplementary Material). Continue reading →

We thank Volta et al for their interest in our recently published study.1 The authors raise relevant questions, which we address below. Continue reading →

We read with interest the article by Skodje et al1 reporting a double-blind placebo-controlled food challenge aimed at establishing whether gluten or fructan, a component of fermentable oligo-, di-, monosaccharides and polyols, evokes gastrointestinal… Continue reading →

We read with great interest the American Gastroenterological Association’s (AGA) updated guidelines on the management of acute pancreatitis (AP)1 and its accompanying technical review.2 AP is the most common pancreatic disease across the globe, occurring in >17 million persons in 2013.3 As such, AP ranks as the top gastroenterologic reason for hospitalization, incurring >$2.6 billion in inpatient costs.4 Since the prior AGA AP guidelines were published in 2007,5 there have been >5000 manuscripts published on AP. Continue reading →